Back to results
US 10,307,404 B1Granted
Ocular formulations for drug-delivery to the posterior segment of the eye
AssigneePanOptica, Inc.
InventorsDavid P. Bingaman, Paul G. Chaney, Martin B. Wax
Life of this patent
Estimating the term…
Abstract
The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
Claims37
A topical, ocular suspension formulation, comprising:
- a. solid particles of an active agent of Formula II:
- or a pharmaceutically acceptable salt thereof, and
- b. pharmaceutically acceptable excipients;
- wherein the active agent or the pharmaceutically acceptable salt is present in about 0.005% to about 5.0% w/v.
1 more element
A topical, ocular, suspension formulation, comprising:
- solid particles of an active agent of Formula II:
- or a pharmaceutically acceptable salt thereof,
- pharmaceutically acceptable excipients selected from hydroxy propyl methyl cellulose (HPMC) and carboxylmethyl cellulose and salts thereof, and
- a nonionic liquid polymer of the alkyl aryl polyether alcohol type,
- wherein the active agent or the pharmaceutically acceptable salt is present in about 0.005% to about 5.0% w/v.
2 more elements
A topical, ocular, suspension formulation, comprising:
- solid particles of an active agent of Formula II:
- or a pharmaceutically acceptable salt thereof,
- pharmaceutically acceptable excipients selected from hydroxy propyl methyl cellulose (HPMC) and carboxylmethyl cellulose and salts thereof, and
- about 0.3%-1% w/v tromethamine,
- about 2% glycerin,
- tyloxapol, and
- poloxamer,
- wherein the active agent or the pharmaceutically acceptable salt is present in about 0.005% to about 5.0% w/v.
5 more elements
Dependencies are inferred from the claim text.